compounds could cause adverse effects, such as inflammatory responses and genotoxic effects (Antunes et al., 2016; Epstein et al., 2009; Ferk et al., 2007; Michee et al., 2013) , mitochondrial dysfunction (Datta et al., 2017) , reproductive dysfunction (Melin et al., 2016) , and developmental defects (Hrubec et al., 2017) . Recent studies show that these compounds, partly due to their high-volume use, are frequently detected in river water, sewage effluent, food products, and human samples of plasma and serum (Bleau and Desaulniers, 1989; Ding and Liao, 2001; Krockel et al., 2003; Li and Brownawell, 2010; Takeoka et al., 2005; Van de Voorde et al., 2012; von Woedtke et al., 1999; Xue et al., 2002; Zhang et al., 2015) . This has raised concern about their impact on the environment and human health. In September 2016, the U.S. Food and Drug Administration removed 19 antimicrobial compounds from consumer antiseptic wash products, but deferred rulemaking for BAC, BET, and PCMX to allow additional time to develop new safety and efficacy data for these 3 antimicrobials (Food and Drug Adminnistration, 2016) . Therefore, it is of critical importance to better understand the effects of these compounds on human health, producing knowledge that could have a significant impact on regulatory policies.
Inflammatory bowel disease (IBD) is characterized by colonic inflammation, and given that it affects $1.6 million people in the United States and $2.5 million people in Europe (Kaplan, 2015) , IBD is a serious health problem in developed countries. IBD patients have elevated risks of developing colon cancer: it was estimated that over 20% of IBD patients could develop colon cancer within 30 years of diagnosis, and over 50% of these patients could die from colon cancer (Terzi c et al., 2010) . Previous studies performed in cultured cells showed that exposure to these compounds caused inflammatory responses and genotoxic effects in vitro (Epstein et al., 2009; Ferk et al., 2007; Michee et al., 2013) . However, to date, the effects of BAC, BET, and PCMX on inflammation and associated tumorigenesis in vivo are unknown. Here, we studied the impact of these 3 antimicrobial compounds on colonic inflammation and colitisassociated colon tumorigenesis using mouse models. Our results demonstrated that exposure to low doses of these antimicrobial compounds, in particular BAC, increased dextran sodium sulfate (DSS)-induced colonic inflammation and azoxymethane (AOM)/DSS-induced colon tumorigenesis in mice, suggesting that these antimicrobial compounds could have potentially adverse effects on gut health.
MATERIALS AND METHODS
Chemicals BAC (purity !95%, catalog # AC215411000), BET (purity 97%, catalog # AC215411000), and PCMX (purity >98.5%, catalog # AC109061000) were purchased from Thermo Fisher Scientific (Waltham, MA). Polyethylene glycol 400 (PEG 400, catalog # PX1286B-2) was purchased from EMD Millipore (Billerica, MA).
Animal Experiments C57BL/6 male mice (age ¼ 6 weeks) were purchased from Charles River (Wilmington, MA) and were maintained in a standard Specific Pathogen Free animal facility at the University of Massachusetts Amherst. All animal procedures were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of Massachusetts. At Charles River, bleach-and chlorine dioxidebased disinfectants are used in the animal facility; and at UMass, hydrogen peroxide-based disinfectants are used to clean surfaces in the animal facility (biological safety cabinets, etc.) and BAC-containing products are used to clean the floor of the animal facility. Therefore, there is little or no exposure of the mice to environmental BAC or other antimicrobials.
DSS-induced colitis model. C57BL/6 mice were administered a modified AIN-93G diet (see diet composition in Supplementary  Table 1) containing 80 ppm BAC, BET, or PCMX (administered at a dose of $8 mg/kg body weight/day, based on a diet of 3 g daily chow), or vehicle control (0.5% polyethylene glycol 400) throughout the whole experiment. The diets were mixed thoroughly so that the compounds were distributed evenly and changed every 3-4 days. After 3 weeks on the diet, the mice were treated with 2% DSS (molecular weight in the range of 36-50 kDa, MP Biomedicals, Solon, OH) in drinking water for 7 days to induce colonic inflammation. At the end of DSS treatment, the mice were sacrificed for analysis of colonic inflammation.
Dose-response study of BAC on DSS-induced colitis. C57BL/6 mice were administered a modified AIN-93G diet containing 5-40 ppm BAC (administered at a dose of $0.5-4 mg/kg body weight/day, based on a diet of 3 g daily chow), or vehicle control throughout the whole experiment. After 3 weeks on the diet, the mice were treated with 2% DSS in water for 7 days to induce colonic inflammation. At the end of DSS treatment, the mice were sacrificed for analysis of colonic inflammation.
AOM/DSS-induced colitis-associated colon cancer model. The mice were administered a diet containing 40 ppm BAC (administered at a dose of $4 mg/kg body weight/day, based on a diet of 3 g daily chow) or vehicle throughout the whole experiment. The diets were mixed thoroughly so that the compounds were distributed evenly and changed every 3-4 days. After 3 weeks on the diet, the mice were given intraperitoneal (ip) injection of 10 mg/kg AOM (Sigma-Aldrich, St. Louis, MO). After 1 week, they were treated with 2% DSS in water for 1 week. On day 50 after the AOM injection, the mice were sacrificed, and blood and colon tissues of the mice were collected for analysis. 
ELISA Analysis of Cytokines
Colon tissues were cut open longitudinally, washed with PBS buffer containing penicillin (100 U/ml) and streptomycin (100 lg/ml) (Lonza, Basel, Switzerland). Distal colon tissues (25 mg) were placed in RPMI 1640 medium (Thermo Fisher Scientific) with 10% fetal bovine serum (FBS, EMD Millipore, Temecula, CA) supplemented with penicillin (100 U/ml) and streptomycin (100 lg/ml), and incubated at 37 C in an atmosphere containing 5% CO 2 for 24 h. The supernatants were collected, and cytokines in the supernatant were measured by the CBA Mouse Inflammation Kit (BD Biosciences) according to the manufacturer's instruction.
Hematoxylin and Eosin Staining
Dissected colon tissues were cut open longitudinally, washed in ice-cold PBS and fixed in 4% formalin (Thermo Fisher Scientific) at 4 C. Tissues were gradually incubated with 15% and 30% sucrose (Thermo Fisher Scientific) at 4 C, then embedded in optimal cutting temperature (OCT) compound (Fisher Healthcare, Houston, TX) and frozen for cryosectioning. OCT-fixed tissue specimens were sliced into 5 lm sections, mounted on glass slides, and air-dried for 1 h. Sections were stained with hematoxylin and eosin staining (Sigma-Aldrich) and examined with light microscopy. The histological scores were evaluated by a blinded observer and given scores according to the following measures: crypt architecture (scored 0-3 with 0 as normal and 3 as most crypt distortion and loss); inflammatory cell infiltration (0-3 with 0 as normal and 3 as most dense inflammatory infiltrate); muscle thickening (0-3 with 0 as normal and 3 being most muscle thickness); goblet cell depletion (0-1 with 0 as goblet cells present and 1 goblet cells depleted) and crypt abscess (0-1 with 0 as absent and 1 present). The histological score is the sum of each score.
Immunohistochemistry Formalin-fixed tissue was embedded in paraffin by using TissueWave TM 2 Microwave Processor (Thermo Fisher Scientific), sliced to 5 mm sections on the same slide, dewaxed in serial xylene solutions (Thermo Fisher Scientific), and rehydrated through graded ethanol solutions (Pharmco-Aaper, Shelbyville, KY). Antigen retrieval was performed by heating the sections in 0.01 M citrate buffer (pH 6.0) to 95 C for 10 min.
Samples were incubated with anti-proliferating cell nuclear antigen (PCNA) antibody (Dako, Carpinteria, CA), anti-cleaved caspase-3 antibody (Cell Signaling Technology, Danvers, MA), anti-b-catenin antibody (BD Biosciences) overnight at 4 C.
Horseradish peroxidase (HRP)-conjugated secondary antibodies were then applied to the sections, followed by the chromogen 4-diaminobenzidine staining according to the instruction of HRP/ DAB (ABC) Detection IHC kit (Abcam, Cambridge, MA). Sections were then counterstained with hematoxylin for 1 min. Positive expression of PCNA, cleaved caspase-3, and b-catenin were observed under light microscope and scored using Fiji software (Schindelin et al., 2012) . Briefly, images of the IHC stained tissues were uploaded to Fiji, and the color was deconvoluted. The intensity numbers of the "Colour_2" image (brown staining) were converted to optical density numbers and then scored relative to control. medium, was added into each well of 96-well plate. After incubation at 37 C for 16 h, the production of secreted embryonic alkaline phosphatase was assessed by reading the absorbance at 620 nm with a plate reader (Molecular Devices, Sunnyvale, CA).
Quantification of Lipopolysaccharide in Plasma
Plasma lipopolysaccharide (LPS) levels were quantified using the LPS ELISA kit (MBS261904, MyBiosource, San Diego, CA) following the manufacturer's instructions.
Real-Time PCR Analysis of 16S rRNA Gene in Liver DNA was extracted from mouse liver samples ($25 mg) using QIAamp DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) following the manufacturer's instruction with the addition of the bead-beating step. The quality of the extracted DNA was measured using a NanoDrop Spectrophotometer (Thermo Fisher Scientific). DNA was subjected to qPCR analysis using a DNA Engine Opticon system (Bio-Rad Laboratories, Hercules, CA) with PowerUp TM SYBR TM Green Master Mix (Thermo Fisher Scientific). DNA was normalized to 5 ng/ll per reaction. The sequences the 16S rRNA primers (Thermo Fisher Scientific) are listed in Supplementary Table 2 .
Data Analysis
Data are expressed as the mean 6 standard error of the mean (SEM). Group comparisons were carried out using one-way analysis of variance (ANOVA) or Student t-test. p values less than .05 were considered statistically significant.
RESULTS

Exposure to BAC and BET Exaggerated DSS-Induced Colitis in Mice
To study the effects of these antimicrobials on colonic inflammation, we used a well-established DSS-induced colitis model in mice. We treated mice with BAC, BET, PCMX (80 ppm in the diet), or vehicle via diet for 21 days. During this period, treatment with the antimicrobial alone did not affect the mouse body weight (Supplementary Figure 1) . We then stimulated the mice with 2% DSS in drinking water for 7 days to induce colonic inflammation (see scheme of animal experiment in Figure 2A ). Exposure to BAC and BET, but not PCMX, increased DSSinduced colonic inflammation in mice. Compared with vehicletreated DSS mice, the BAC-treated DSS mice showed increased weight loss on days 6-7 after initiation of DSS stimulation (p < .05), whereas BET and PCMX had no such effect ( Figure 2B ). Exposure to all 3 antimicrobial compounds caused a reduction in colon length (p < .001, Figure 2C ), which is a biomarker of colitis. Histology analysis showed that exposure to BAC and BET, but not PCMX, increased DSS-induced colonic inflammation, with increased crypt damage and inflammatory cell infiltration into colon tissues (p < .05, Figure 2D ). We next analyzed the colon at the cellular and molecular level. Immune cells and cytokines play critical roles in the development of colitis (Terzi c et al., 2010) . Flow cytometry analysis showed that exposure to BAC and BET, but not PCMX, increased infiltration of immune cells-including leukocytes (CD45þ), macrophages (CD45þ, F4/ 80þ), and neutrophils (CD45þ, Gr1þ)-into colon tissues (p < .05, Figure 2E ). ELISA analysis showed that exposure to BAC and BET, but not PCMX, increased concentrations of interleukin 6 (IL-6), a proinflammatory cytokine, in colonic explant (p < .05, Figure 2F ). Consistent with the ELISA result, qRT-PCR analysis showed that exposure to BAC increased gene expression of Il-6 in colon tissues (p < .01); BET also increased Il-6 expression, but the effect was not statistically significant, and PCMX had no effect ( Figure 2G ). These results suggest that BAC and BET, but not PCMX, were able to increase DSS-induced colonic inflammation.
Dose-Dependent Effects of BAC on DSS-Induced Colitis in Mice
Among the 3 compounds, BAC showed the most potent effect on DSS-induced colonic inflammation, and we further studied its dose-dependent effect on colonic inflammation (see scheme of animal experiment in Figure 3A) . The results showed that exposure to 20-40 ppm of BAC in the diet ($2-4 mg/kg body weight/day) caused a reduction in colon length (p < 0.05, Figure 3B ). Flow cytometry analysis showed that exposure to BAC increased immune cell infiltration into the colon in a dosedependent manner ( Figure 3C ). These results suggest that even at lower doses, BAC was able to increase DSS-induced colonic inflammation.
Exposure to BAC Exaggerated AOM/DSS-Induced Colon Tumorigenesis in Mice
After demonstrating that exposure to BAC showed the most potent effect on DSS-induced colonic inflammation, we studied its effect on colitis-associated colon tumorigenesis using an AOM/ DSS-induced colon tumorigenesis model in mice (see scheme of animal experiment in Figure 4A ). Compared with vehicletreated mice, the mice treated with BAC had increased mortality: the overall mortality for the control group was 21% (3 of 14 mice died in the control group), and mortality for the BAC group was 60% (9 of 15 mice died in the BAC group) ( Figure 4B ). Exposure to BAC increased the spleen weight, suggesting increased systemic inflammation: the spleen weight of vehicletreated mice was 135 6 14 mg (mean 6 SEM) versus 191 6 20 mg for BAC-treated mice (p < .05, Figure 4C ). Exposure to BAC also increased the average tumor size (1.8 6 0.3 cm 2 for the control group vs 3.5 6 0.5 cm 2 for the BAC group, p ¼ .008), yet had no effect on the numbers of tumors per mouse (8.6 6 1.3 for the control group vs 10 6 1.8 for the BAC group, p ¼ .539), although the total tumor burden in mice did increase (14.8 6 3.7 cm 2 for the control group vs 35 6 8.8 cm 2 for the BAC group, p ¼ .033) ( Figure 4D ). The qRT-PCR analysis showed that treatment with BAC increased the gene expressions of several protumorigenic genes, such as c-Jun, cyclin D, and b-catenin, in colon tumors (p < .05, Figure 4E ). Consistent with the qRT-PCR result, immunohistochemistry showed that b-catenin protein levels were increased in colon tumors of BAC-treated mice (p < .01). In addition, we found that the PCNA protein levels were increased (p < .01), whereas cleaved caspase-3 protein levels were decreased (p < .001), in BAC-treated colon tumors, which suggests that exposure to BAC increased tumor proliferation and decreased tumor apoptosis ( Figure 4F ). Together, these results demonstrate that exposure to BAC increased AOM/DSS-induced colitis-associated colon tumorigenesis in mice.
Exposure to BAC Increased Activation of TLR4 in Systemic Circulation
Innate immunity receptors, in particular TLR4, play critical roles in regulating colonic inflammation and associated colon tumorigenesis (Dheer et al., 2016; Khan et al., 2006) . We studied the effects of BAC exposure on TLR4 signaling, by testing the potential of the plasma from BAC-treated DSS mice on the activation of TLR4. Using a TLR4 reporter cell line (HEK-Blue TM mTLR4), we found that, compared with the plasma from vehicle-treated DSS mice, the plasma from BAC-treated DSS mice caused enhanced activation of TLR4 (p ¼ .013, Figure 5A ). Consistent with the TLR4 reporter assay, we found that the BAC-treated DSS mice had higher plasma levels of LPS, a known ligand of TLR4 (p ¼ .040, Figure 5B ) (Lu et al., 2008) . In addition, we found that the liver tissues from BAC-treated DSS mice had higher levels of bacterial DNA, as assessed by qPCR analysis of 16S rRNA gene (p ¼ .064, Figure 5C ). These results demonstrate that exposure to BAC enhanced translocation of bacterial products from the gut into the circulation and other organs. Previous studies showed that an enhanced level of bacterial products in the systemic circulation could be due to compromised mucosal permeability (Bischoff et al., 2014 ). Therefore, we tested the effect of BAC exposure on the expression of colonic proteins involved in regulating intestinal barrier function. We found that compared with vehicletreated DSS mice, the BAC-treated DSS mice had a dramatic reduction of colonic expression of Occludin (p ¼ .006, Figure 5D ), which encodes a protein that plays an important role in maintaining mucosal barrier function (Feldman et al., 2005) . Together, these results showed that exposure to BAC enhanced activation of TLR4 in the systemic circulation, in part through impairing intestinal barrier function and enhancing bacterial products in the circulation.
DISCUSSION
In the last century, there has been a dramatic increase in the incidence and prevalence of IBD in the United States and other countries (Molodecky et al., 2012) . This rapid development suggests that environmental factors could contribute to the growing incidence of IBD around the globe (Chassaing et al., 2015; Danese et al., 2004; Devkota et al., 2012) . In support of this hypothesis, recent studies showed that exposure to certain dietary and environmental compounds increased the development of IBD in animal models (Chassaing et al., 2015; Devkota et al., 2012) . Due to the increased incidences of IBD and the potential lethal consequence of IBD-associated colon cancer, it is of practical importance to discover new environmental risk factors for these diseases. BAC, BET, and PCMX are antimicrobial compounds used in many consumer products. Previous studies showed that these compounds could cause some adverse effects, including inflammatory responses and genotoxic effects (Antunes et al., 2016; Epstein et al., 2009; Ferk et al., 2007; Michee et al., 2013) , mitochondrial dysfunction (Datta et al., 2017) , reproductive dysfunction (Melin et al., 2016) , and developmental defects (Hrubec et al., 2017) . In this study, we studied their effects on IBD and IBDassociated colon tumorigenesis in mouse models. Here, our central finding is that short-term exposure to low-dose antimicrobial compounds, in particular BAC and BET, increased colitis and/or colitis-associated colon tumorigenesis in mice, which suggests potential adverse effects from these compounds. Among the tested 3 compounds, PCMX showed the least severe adverse effect; however, in the DSS colitis experiment, exposure to PCMX also increased DSS-induced colon length reduction. This suggests some adverse effects on gut health may result from PCMX. Our results are in agreement with previous studies that illustrated proinflammatory effects of BAC in vitro. These studies showed that treatment with BAC increased production of proinflammatory cytokines in immortalized human conjunctival and corneal epithelial cells, and increased phagocytosis, macrophage migration, and production of proinflammatory cytokines in THP-1-derived macrophages (Epstein et al., 2009; Michee et al., 2013) . Therefore, the enhancing effects of BAC on colitis and colitis-associated colon cancer could be, at least in part, due to its proinflammatory effect. To our knowledge, this study is the first animal study to demonstrate that these antimicrobial compounds have adverse effects on gut health. A better understanding of their actions on colonic inflammation and colon cancer could help to establish regulatory policies for these compounds.
Among the 3 tested antimicrobial compounds, PCMX showed the least adverse effect on DSS-induced colitis, with little impact on colonic inflammation. There could be several reasons for the different effects of PCMX compared with BAC and BET. PCMX, but not BAC and BET, contains a phenolic group, which is highly prone to rapid metabolism by phase II detoxification enzymes such as glucuronosyltransferase and sulfotransferase, leading to formation of water-soluble conjugated metabolites (glucuronides and sulfates) and excretion via the urine. Indeed, previous studies in dogs showed that PCMX was rapidly metabolized to glucuronide-and sulfate-conjugates and excreted in urine (Dorantes and Stavchansky, 1992) . Therefore, the lack of effect of PCMX on colonic inflammation in our studies could be in part due to its poor metabolic stability. In addition, compared with BAC and BET, PCMX has a much smaller size, which could impact its absorption and duration in the gastrointestinal tract. To date, the metabolism and pharmacokinetics of these antimicrobial compounds in vivo are not well investigated. Further studies could help to address the structure-activity relationships of the antimicrobials, which could help to design better antimicrobial ingredients.
A critical question in this study is whether the effects observed in the animal models represent responses that would arise from human exposure. An examination of the comparability of our administered dosage to investigated acceptable daily intake (ADI) levels can shed light on this question. In our experiment, we found that exposure to 40 ppm of BAC in diet (administering BAC at a dose of $4 mg/kg/day, based on a diet of 3 g daily chow) increased colitis-associated colon tumorigenesis in mice. The dose used in our animal experiment is the lowest among reported animal studies of BAC (Melin et al., 2016; Zhang et al., 2015) . To put the dose in perspective, previous studies showed that the no-observed-adverse-effect level of BAC was 192 mg/kg body weight/day from a 90-day study in CD-1 mice (Food and Drug Adminnistration, 2014) , which leads to a calculated ADI of BAC of $1.9 mg/kg body weight/day (Lu, 1988) . Therefore, the dose of BAC used in the animal experiments is comparable with previously investigated ADI values. This supports the biological relevance of our findings. We recognize the difficulties in translating the animal data to human studies. There are several challenges to using animal models to study human exposure to these consumer antimicrobial compounds. First, accurate assessment of the degree, type, and variation of exposure levels of these compounds in humans is largely lacking. Second, dermal exposure (eg, by using soaps) and oral exposure (eg, by using mouthwash or toothpaste) to these antimicrobial compounds could lead to different biological responses. Indeed, a recent study showed that usage of antibacterial toothpaste, but not antibacterial soaps, modulated gut microbiota in humans (Ribado et al., 2017) . Third, after exposure to these compounds, there could be a high degree of interindividual variation in the metabolism and secretion of these compounds. Based on our studies, it is feasible to conclude that long-term high-dose exposure to these antimicrobial compounds could lead to adverse effects on gut health. Previous studies have shown that BAC and BET were frequently detected at high levels in grapefruit seed extract (GSE), a popular dietary supplement, despite the fact that these compounds are not permitted to use as food additives (Takeoka et al., 2005; von Woedtke et al., 1999) . Notably, von Woedtke et al. showed that 5 of 6 commercial GSE products contained 1.3%-10% of BET. Frequent consumption of these contaminated dietary products could lead to high-dose exposure to BET and might cause adverse effects on gut health.
TLRs are important innate immunity receptors and play critical roles in regulating colonic inflammation and associated colon tumorigenesis (Cario, 2010; Terzi c et al., 2010) . Our results show that during DSS-induced colitis, exposure to BAC impaired intestinal barrier function and thus enhanced translocation of bacterial products (eg, LPS and bacteria) from the gut into the systemic circulation and other organs, resulting in enhanced activation of TLR4 in the systemic circulation. Previous studies showed that enhanced activation of TLR4 is associated with increased progression of colitis and colitis-associated colon cancer (Fukata et al., 2007; Fukata et al., 2005; Khan et al., 2006) . Indeed, compared with WT mice, genetically engineered mice lacking TLR4 had attenuated, whereas genetically engineered mice with overexpression of TLR4 had enhanced, the progression of DSS-induced colitis and/or AOM/DSS-induced colon cancer (Dheer et al., 2016; Fukata et al., 2007 Fukata et al., , 2005 , though there are inconsistent results (Matharu et al., 2009) . Together, these results support that TLR4 signaling might play a role in the observed procolitis and proneoplastic effects of BAC.
In summary, our study showed that exposure to low-dose antimicrobial compounds, particularly BAC, increased colonic inflammation and colon cancer in mice. These studies suggest that further studies are needed to better characterize the effects of these compounds on gut health in order to develop sound regulatory policies for these compounds.
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